Ultime notizie per Soluna Holdings (NASDAQ:SLNHP) Azioni

Soluna Holdings Inc is a U.S.-based company that conducts operations through its subsidiary. The group is engaged in the mining of cryptocurrency through data centers that can be powered by renewable energy sources. The data centers buy every excess megawatt to use for batch-oriented, computing-intensive processes such as cryptocurrency mining or machine learning which is a low-risk and low-friction solution to use as a smartphone.

Soluna Holdings, Inc. - 9.0% Series A Cumulative Perpetual Preferred Stock

Soluna Holdings Inc

As of month-end, the Company operated approximately 185,000 bitcoin miners in data centers for both self-mining and hosting, representing a total energized hash rate of 21.8 EH/s. &nbsp;

News

Core Scientific, Inc. - Class A Common Stock

CORZ

Core Scientific Says It Earned 369 Bitcoin In October From Its Owned Fleet Of Miners Vs. 345 In September

Select October 2024 Highlights
<ul>
<li>Record total average daily volume ("ADV") of $46.2 billion increased 40% compared to the prior year, and increased 2% compared to September 2024. These strong results were driven by total credit ADV of $15.0 billion, representing an increase of 19% compared to the prior year, and a decrease of 9% compared to September 2024. Record total rates ADV of $31.2 billion, which increased 54% compared to the prior year, and increased 9% compared to September 2024 levels, also contributed to the strong performance in October 2024.</li>
<li>Record total trading volume of $1.0 trillion on the platform increased 47% compared to the prior year, and increased 12% compared to September 2024.</li>
</ul>

MKTX

MarketAxess Announced Trading Volume For October 2024 With Total Average Daily Volume Of $46.2B, Up 40% YoY And +2% Compared To September 2024

NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.01 by 400 percent. The company reported quarterly sales of $167.824 million which beat the analyst consensus estimate of $167.010 million by 0.49 percent. This is a 10.44 percent increase over sales of $151.954 million the same period last year.

Earnings

Earnings Beats

NeoGenomics Q3 2024 Adj. EPS $0.05 Beats $0.01 Estimate, Sales $167.824M Beat $167.010M Estimate

Leerink Partners analyst Christopher Liu downgrades IDEAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>) from Outperform to Market Perform and lowers the price target from $41 to $27.

Downgrades

Price Target

Analyst Ratings

IDYA

Leerink Partners Downgrades IDEAYA Biosciences to Market Perform, Lowers Price Target to $27

Pseudonymous crypto analysts DonAlt and CryptoCred explored Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) price trends and the impact of <a href="https://www.benzinga.com/news/24/11/41733346/obamas-former-campaign-manager-alarmed-by-early-voting-numbers-as-harris-trump-fight-close-battle-re">Tuesday&#8217;s presidential election</a>.
Bitcoin's Expected Trajectory
In the latest &#8216;Technical Roundup&#8217; <a href="https://www.youtube.com/watch?v=IhonU0vEFQE&amp;pp=ygURdGVjaG5pY2FsIHJvdW5kdXA%3D">episode</a>, DonAlt noted Bitcoin's recent surge to close to its all-time high before retreating below $70,000, calling the monthly close "catastrophic" after a key resistance retest.
He projected $49,000 as the first support level in the short term, with more robust support near $35,000 on a monthly timeframe, and in an extreme scenario, a possible drop to $16,000.
DonAlt attributes recent sluggish crypto market activity to positioning ahead of a potential Trump victory. He <a href="https://x.com/CryptoDonAlt/status/1853452002983813251">cautioned</a> on X that a Trump win might bring only modest short-term upside for Bitcoin, while a loss could trigger a sell-off, with a Harris win potentially causing an even steeper decline. Emphasizing flexibility, DonAlt highlighted the need for strategic preparation as election results unfold.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41720318/bitcoin-on-the-evening-of-the-election-heres-how-it-performed-in-2012-2016-and-2020">Bitcoin On The Evening Of The Election—Here&#8217;s How It Performed In 2012, 2016 And 2020</a>
Ethereum's Play
DonAlt also commented on Ethereum's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) underperformance relative to Bitcoin, stressing the dependency of ETH/BTC strength on Bitcoin's movement. He shared his open position in a SOL/BTC trade.
Given the election uncertainty, DonAlt concluded, "I'm not going to trade in the next weeks, maybe months," stressing the importance of caution in the current environment.
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41709166/bitcoin-to-hit-100-000-by-january-2025-could-black-hole-effect-push-the-largest-crypto-to-">Bitcoin To Hit $100,000 By January 2025? Could &#8216;Black Hole Effect&#8217; Push The Largest Crypto To Never-Before-Seen Levels</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

Veteran Traders Share 'Presidential Election Crypto Trading Roadmap,' Predict Heavy Volatility

<a href="https://www.aboutamazon.com/news/transportation/amazon-drone-delivery-arizona" title="https://www.aboutamazon.com/news/transportation/amazon-drone-delivery-arizona">https://www.aboutamazon.com/news/transportation/amazon-drone-delivery-arizona</a>

AMZN

Amazon Says Customers In West Valley Phoenix Metro Area Now Receiving Prime Air Drone Deliveries

Coloplast (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLPBY#OTC">CLPBY</a>) reported quarterly earnings of $0.08 per share. This is unchanged from the same period last year. The company reported $1.02 billion in sales this quarter. This is a 12.64 percent increase over sales of $909.09 million the same period last year.

CLPBY

Coloplast Q4 EPS $0.08, Same YoY, Sales $1.02B Up From $909.09M YoY

Biotech

Health Care

General

RNAZ

Transcode Therapeutics Has Received Notice From The Nasdaq Stock Market To Grant Transcode's Request To Continue Its Listing On The Nasdaq Stock Market Subject To Certain Conditions To Regain Compliance

The Company anticipates releasing its financial results for the six months ended June 30, 2024, by the end of November.
 &nbsp;

HUBC

HUB Security Says Making Progress On All Fronts, With Steady Advancement In Existing Contracts; Aims To Strategically Position Itself For Significant Penetration Into US Market In Q1 2025

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the financials sector.
<h3 class="wp-block-heading">Lincoln National Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNC#NYSE">LNC</a>)</h3>
<ul>
<li>Dividend Yield: 5.47%</li>
<li>Wells Fargo analyst Elyse Greenspan maintained an Equal-Weight rating and raised the price target from $28 to $29 on Oct. 10. This analyst has an accuracy rate of 75%.</li>
<li>Barclays analyst Alex Scott maintained an Equal-Weight rating and raised the price target from $35 to $36 on Oct. 8. This analyst has an accuracy rate of 66%.</li>
<li>Recent News: On Oct. 31, Lincoln National posted better-than-expected quarterly earnings.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1">latest LNC news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="918" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044515/image-24.png" alt="" class="wp-image-629784" style="width:694px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044515/image-24.png 918w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044515/image-24-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044515/image-24-768x704.png 768w" sizes="(max-width: 918px) 100vw, 918px" /></a></figure>
<h3 class="wp-block-heading">Heritage Commerce Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTBK#NASDAQ">HTBK</a>)</h3>
<ul>
<li>Dividend Yield: 5.44%</li>
<li>Piper Sandler analyst Andrew Liesch maintained an Overweight rating and raised the price target from $10 to $12 on July 26. This analyst has an accuracy rate of 78%.</li>
<li>Keefe, Bruyette &amp; Woods analyst Wood Lay maintained an Outperform rating and increased the price target from $10.5 to $11.5 on July 26. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On Oct. 24, Heritage Commerce posted in-line quarterly earnings.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1">latest HTBK news.</a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044644/image-25.png" alt="" class="wp-image-629786" style="width:655px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044644/image-25.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044644/image-25-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044644/image-25-768x715.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<h3 class="wp-block-heading">Columbia Banking System, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>)</h3>
<ul>
<li>Dividend Yield: 5.19%</li>
<li>Truist Securities analyst Brandon King maintained a Hold rating and raised the price target from $28 to $30 on Oct. 28. This analyst has an accuracy rate of 81%.</li>
<li>RBC Capital analyst Jon Arfstrom maintained a Sector Perform rating and increased the price target from $29 to $31 on Oct. 25. This analyst has an accuracy rate of 79%.</li>
<li>Recent News: On Oct. 24, Columbia Banking System posted better-than-expected quarterly results.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1"> trend in COLB stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="916" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044902/image-26.png" alt="" class="wp-image-629787" style="width:614px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044902/image-26.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044902/image-26-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044902/image-26-768x698.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41735699/archer-daniels-midland-yum-brands-and-3-stocks-to-watch-heading-into-tuesday">Archer-Daniels-Midland, Yum! Brands And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>

Dividends

Pre-Market Outlook

Markets

Trading Ideas

COLB

HTBK

Wall Street's Most Accurate Analysts Spotlight On 3 Financial Stocks Delivering High-Dividend Yields

Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.54) by 12.96 percent. This is a 14.55 percent increase over losses of $(0.55) per share from the same period last year. The company reported quarterly sales of $4.89 million which beat the analyst consensus estimate of $3.35 million by 46.09 percent. This is a 47.94 percent increase over sales of $3.31 million the same period last year.

STOK

Stoke Therapeutics Q3 2024 GAAP EPS $(0.47) Beats $(0.54) Estimate, Sales $4.89M Beat $3.35M Estimate, $269.2M In Cash, Cash Equivalents, And Marketable Securities

Keybanc analyst Aleksey Yefremov maintains Entegris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>) with a Overweight and lowers the price target from $164 to $154.

ENTG

Keybanc Maintains Overweight on Entegris, Lowers Price Target to $154

JP Morgan analyst Tessa Romero initiates coverage on Upstream Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPB#NASDAQ">UPB</a>) with a Overweight rating and announces Price Target of $38.

Initiation

JP Morgan Initiates Coverage On Upstream Bio with Overweight Rating, Announces Price Target of $38

Guidance

VERV

Verve Therapeutics Ended Q3 2024 With Cash, Cash Equivalents, And Marketable Securities Of $539.9M With Cash Runway Through 2026

R1 RCM Says It Is Not Providing Financial Guidance Due To Previously Announced Proposed Acquisition Of R1

2024 Outlook
Today, Sotera Health is reaffirming the following 2024 outlook ranges previously provided:
<ul>
<li>Net revenues and Adjusted EBITDA growth in the range of 4.0% to 6.0%,</li>
<li>Interest Expense in the range of $165 million to $175 million,</li>
<li>Tax rate applicable to Adjusted Net Income(3) in the range of 31.5% to 34.5%,</li>
<li>Adjusted EPS in the range of $0.67 to $0.75,</li>
<li>A weighted-average fully diluted share count in the range of 283 million to 285 million shares, and</li>
</ul>
The following range in the 2024 outlook is being updated:
<ul>
<li>Capital expenditures are now expected to be in the range of $175 million to $185 million, from previous guidance of $205 million to $225 million</li>
</ul>

Sotera Health Co Reaffirmed Its 2024 Guidance Of Net Revenue Growth Of 4%-6%; Adj. EPS Of $0.67-$0.75 Vs. $0.72 Est.; Sees Capital Expenditures Of $175M-$185M (Priro $205M-$225M)

Verve Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.69) by 14.49 percent. This is a 18.06 percent increase over losses of $(0.72) per share from the same period last year. The company reported quarterly sales of $6.87 million which beat the analyst consensus estimate of $2.81 million by 144.31 percent. This is a 120.24 percent increase over sales of $3.12 million the same period last year.

Verve Therapeutics Q3 2024 GAAP EPS $(0.59) Beats $(0.69) Estimate, Sales $6.87M Beat $2.81M Estimate

R1 RCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCM#NASDAQ">RCM</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.13) by 61.54 percent. The company reported quarterly sales of $656.80 million which beat the analyst consensus estimate of $634.17 million by 3.57 percent. This is a 14.66 percent increase over sales of $572.80 million the same period last year.

R1 RCM Q3 2024 GAAP EPS $(0.05) Beats $(0.13) Estimate, Sales $656.80M Beat $634.17M Estimate

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="4">Summary of Fourth Quarter 2024 Guidance (Unaudited, in millions, except per share amounts)(1)</td>
</tr>
<tr>
<td colspan="1">IFRS</td>
<td>Share-based compensation</td>
<td colspan="2">Non-IFRS (2)</td>
</tr>
<tr>
<td>Net revenue</td>
<td colspan="1">$1,800 - $1,850</td>
<td>—</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Gross profit</td>
<td colspan="1">$417 - $468</td>
<td>$13 - $15</td>
<td>$432 - $481</td>
</tr>
<tr>
<td>Gross margin(3) (mid-point)</td>
<td>24.3%</td>
<td>25.0%</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Operating profit</td>
<td colspan="1">$177 - $256</td>
<td>$45 - $55</td>
<td>$232 - $301</td>
</tr>
<tr>
<td>Operating margin(3) (mid-point)</td>
<td>11.9%</td>
<td>14.6%</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Net income (4)</td>
<td colspan="1">$161 - $236</td>
<td>$45 - $55</td>
<td>$216 - $281</td>
</tr>
<tr>
<td>Net income margin(3) (mid-point)</td>
<td>10.9%</td>
<td>13.6%</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Diluted EPS</td>
<td colspan="1">$0.29 - $0.43</td>
<td colspan="2">$0.39 - $0.51</td>
</tr>
</tbody>
</table>
</figure>

GlobalFoundries Expects Q4 Net Revenue Of $1.80B-$1.85B Vs $1.73B Est, Adj EPS Of $0.39-$0.51 Vs $0.33 Est

JP Morgan analyst Tessa Romero downgrades Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) from Overweight to Neutral and lowers the price target from $18 to $15.

Comments

Soluna Holdings

Notizie

Ultime notizie per Soluna Holdings (NASDAQ:SLNHP) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO